poisar

Stock

Dianthus Therapeutics, Inc. DNTH

$115.80+5.66%

Overview

DNTH market data

Price History

DNTH price chart

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$4.20
Diluted earnings per share over the trailing twelve months.
Beta
1.86
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
-10,097.0%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$19.00 – $114.55
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $6.2B · P/B 3.58 · P/S 3,253.54.

Company News

10 captured
Truist Securities Maintains Buy on Dianthus Therapeutics, Raises Price Target to $128Benzinga · Aug 6, 2026, 3:55 PM
HC Wainwright & Co. Maintains Buy on Dianthus Therapeutics, Raises Price Target to $158Benzinga · Aug 6, 2026, 11:01 AM
Wedbush Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $122Benzinga · Aug 5, 2026, 1:22 PM
Dianthus Therapeutics Q2 EPS $(0.90) Misses $(0.88) Estimate, Sales $761.000K Beat $258.583K EstimateBenzinga · Aug 4, 2026, 8:21 PM
Dianthus Therapeutics Announces New Pipeline Candidate, DNTH312 for Autoimmune Disorders; The Company Expects DNTH312 to be Phase 1 Ready By End Of 2027Benzinga · Aug 4, 2026, 11:10 AM
Dianthus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)Globenewswire Inc · Aug 3, 2026, 10:15 PM
Evercore ISI Group Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $134Benzinga · Aug 3, 2026, 3:03 PM
Why Is Dianthus Therapeutics Stock Trading Higher On Friday?Benzinga · Jun 12, 2026, 5:25 PM
8-K filing — Dianthus Therapeutics, Inc. /DE/ (DNTH)SEC EDGAR · Jun 12, 2026, 11:00 AM
Sanofi Trial Setback May Reinforce Argenx Vyvgart's Position In CIDP, Analyst SaysBenzinga · Jun 11, 2026, 2:30 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock